Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 9:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 1,852 matching trials from the live ClinicalTrials.gov search.
Conditions
Major Depressive Disorder
Interventions
Active transcutaneous spinal direct current stimulation, Sham transcutaneous spinal direct current stimulation
Device
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Mason, Ohio
Conditions
Mild Cognitive Impairment, Major Depressive Disorder, Alzheimer's Disease
Interventions
es-citalopram, Memantine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
50 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
New York, New York
Conditions
Major Depressive Disorder, Alzheimer Disease, Dementia, Nervous System Diseases, Memory Disorders, Depressive Disorder
Interventions
Transcranial direct current stimulation (tDCS); Transcranial alternating current stimulation (tACS)
Device
Lead sponsor
Hebrew SeniorLife
Other
Eligibility
55 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Major Depressive Disorder
Interventions
Zelquistinel
Drug
Lead sponsor
Syndeio Biosciences, Inc
Industry
Eligibility
18 Years to 64 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
32
States / cities
Phoenix, Arizona • Tucson, Arizona • Montclair, California + 27 more
Conditions
Schizophrenia, Major Depressive Disorder (MDD), Bipolar Disorder
Interventions
SEP-380135, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Los Alamitos, California
Completed Not applicable Interventional Accepts healthy volunteers Results available

Predictors of Treatment Outcome With Cognitive Behavioral Therapy for Depression

NCT01922219
Conditions
Major Depressive Disorder
Interventions
Cognitive Behavioral Therapy
Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
1
States / cities
New York, New York
Conditions
Depressive Disorder, Major
Interventions
memantine, Placebo Oral Capsule
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Stanford, California
Completed Not applicable Interventional Accepts healthy volunteers

Cellular Aging and Neurobiology of Depression Study

NCT00285935
Conditions
Major Depressive Disorder
Interventions
Standard Clinical Care with an SSRI
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years to 60 Years
Enrollment
228 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2025
U.S. locations
1
States / cities
San Francisco, California
Conditions
Major Depressive Disorder, Dysthymia
Interventions
Stepped Care IPT-A (SCIPT-A), Treatment as Usual
Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
13 Years to 20 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
New York, New York
Active, not recruiting No phase listed Observational

Open Label Optimization Study

NCT05819021
Conditions
Major Depressive Disorder
Interventions
SAINT® Neuromodulation System (NMS)
Device
Lead sponsor
Magnus Medical
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
7
States / cities
Costa Mesa, California • Los Angeles, California • Sunnyvale, California + 3 more
Conditions
Depressive Disorder, Major
Interventions
Esketamine, Placebo, Standard of Care
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
18
States / cities
San Diego, California • Farmington, Connecticut • Miami, Florida + 14 more
Conditions
Major Depressive Disorder
Interventions
Desvenlafaxine succinate sustained release 50 mg, Desvenlafaxine succinate sustained release 25 mg, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
874 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
21
States / cities
Beverly Hills, California • Encino, California • Los Alamitos, California + 16 more
Conditions
Treatment Resistant Depression, Major Depressive Episode, Major Depression, Major Depressive Disorder, Bipolar Disorder, Bipolar Depression, Obsessive-Compulsive Disorder
Interventions
Electroconvulsive Therapy (ECT), Transcranial Magnetic Stimulation (TMS), Ketamine, Esketamine, Deep Transcranial Magnetic Stimulation (dTMS)
Device · Drug
Lead sponsor
Mark Niciu
Other
Eligibility
18 Years to 99 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2050
U.S. locations
1
States / cities
Iowa City, Iowa
Conditions
Major Depressive Disorder
Interventions
Cariprazine, Placebo, Antidepressant Therapy (ADT)
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
752 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
58
States / cities
Dothan, Alabama • Little Rock, Arkansas • Anaheim, California + 50 more
Conditions
Depression, Dementia, Mild Cognitive Impairment, Treatment Resistant Depression, Major Depressive Disorder, Treatment-Refractory Depression, Late Life Depression, Geriatric Depression
Interventions
Aripiprazole Augmentation, Bupropion Augmentation, Switch to bupropion, Lithium Augmentation, Switch to nortriptyline
Drug
Lead sponsor
Centre for Addiction and Mental Health
Other
Eligibility
60 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
3
States / cities
Los Angeles, California • St Louis, Missouri • New York, New York
Conditions
Major Depressive Disorder, Major Depression, Unipolar Depression
Interventions
fluoxetine or desipramine
Drug
Lead sponsor
National Institute of General Medical Sciences (NIGMS)
NIH
Eligibility
18 Years to 70 Years
Enrollment
700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2008
U.S. locations
1
States / cities
Miami, Florida
Conditions
Severe Mood Dysregulation
Interventions
IPT-MBD
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
12 Years to 17 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Completed Not applicable Interventional Accepts healthy volunteers

Examining the Effects of Reduced Environmental Stimulation on Anxiety

NCT03051074
Conditions
Generalized Anxiety Disorder, Agoraphobia, Panic Disorder, PostTraumatic Stress Disorder, Social Anxiety Disorder, Major Depressive Disorder
Interventions
Floating, Comparison
Behavioral
Lead sponsor
Laureate Institute for Brain Research, Inc.
Other
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Tulsa, Oklahoma
Conditions
Rheumatoid Arthritis, Cannabis
Interventions
200mg Cannabidiol by capsules twice daily, 400mg Cannabidiol by capsules twice daily, Placebo capsules
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Major Depressive Disorder
Interventions
Desvenlafaxine Succinate
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,403 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
53
States / cities
Birmingham, Alabama • Mesa, Arizona • Peoria, Arizona + 46 more
Enrolling by invitation Not applicable Interventional

Mindfulness-Based Therapy for Serious Mental Illness

NCT06880796
Conditions
Serious Mental Illness, Schizophrenia, Major Depressive Disorder, Bipolar Disorder
Interventions
Mindfulness-based therapy, Treatment as Usual (TAU)
Behavioral
Lead sponsor
Butler Hospital
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Providence, Rhode Island
Conditions
Depressive Disorder, Major
Interventions
Testosterone gel, Placebo
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
30 Years to 65 Years · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Belmont, Massachusetts
Conditions
Chronic Insomnia Disorder
Interventions
Mayo Clinic Cognitive Behavioral Therapy for Insomnia (CBT-I), Acoustic Resonance Therapy (ART)
Behavioral · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
22 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Completed Not applicable Interventional Results available

Wake Therapy in the Treatment of Depression

NCT01431573
Conditions
Major Depressive Disorder, Bipolar Disorder
Interventions
Wake Therapy, light box, Lithium
Behavioral · Device · Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
New York, New York